TD Private Client Wealth’s Phibro Animal Health PAHC Stock Holding History

TD Private Client Wealth’s Portfolio PAHC Stock Details PAHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12	Closed	-$230	–	1232
2022 Q2	$230	Hold	12	–	–	﹤0.01%	1220
2022 Q1	$239	Hold	12	–	–	﹤0.01%	1261
2021 Q4	$245	Hold	12	–	–	﹤0.01%	1157
2021 Q3	$258	Hold	12	–	–	﹤0.01%	1204
2021 Q2	$347	Buy	+12	New	+$325	﹤0.01%	1206

Other funds holding PAHC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TD Private Client Wealth's PAHC Position: Q3 2022 in Review

TD Private Client Wealth sold out of Phibro Animal Health (PAHC) in Q3 2022, closing a stake of 12 shares — an estimated $230 sold.

TD Private Client Wealth first reported a position in PAHC in Q2 2021 and held it in 5 quarters. The position peaked at $347 in Q2 2021. 149 funds tracked by Wall St. Rank hold PAHC as of Q3 2022.

TD Private Client Wealth reported no remaining Phibro Animal Health position as of Q3 2022 after selling out during the quarter.
TD Private Client Wealth sold 12 Phibro Animal Health shares in Q3 2022, an estimated $230.
TD Private Client Wealth first reported a position in Phibro Animal Health in Q2 2021 and held it in 5 quarters.
TD Private Client Wealth's Phibro Animal Health position peaked at $347 in Q2 2021.
149 funds tracked by Wall St. Rank held Phibro Animal Health as of Q3 2022.

Based on TD Private Client Wealth's 13F filing for Q3 2022, filed 16 Aug 2024.